Livforsakringsbolaget Skandia Omsesidigt Invests $794,000 in Stryker Corporation $SYK

Livforsakringsbolaget Skandia Omsesidigt purchased a new stake in Stryker Corporation (NYSE:SYK) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 2,515 shares of the medical technology company’s stock, valued at approximately $794,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Gables Capital Management Inc. acquired a new stake in shares of Stryker during the second quarter worth $25,000. Kilter Group LLC acquired a new position in shares of Stryker in the second quarter valued at about $25,000. Godfrey Financial Associates Inc. bought a new position in Stryker during the fourth quarter worth about $26,000. Sankala Group LLC bought a new position in Stryker during the fourth quarter worth about $26,000. Finally, Compass Financial Management LLC acquired a new stake in Stryker in the 2nd quarter worth about $27,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Price Performance

Stryker stock opened at $331.32 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $396.86. The stock has a market capitalization of $127.08 billion, a P/E ratio of 34.33, a price-to-earnings-growth ratio of 2.11 and a beta of 0.76. The stock has a fifty day moving average of $329.10 and a 200-day moving average of $331.47.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating the consensus estimate of $3.49 by $0.20. The business had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.Stryker’s revenue was up 9.4% compared to the same quarter last year. During the same period last year, the firm posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, sell-side analysts expect that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker’s dividend payout ratio is currently 36.48%.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on SYK shares. Citizens Jmp cut their price objective on shares of Stryker from $440.00 to $400.00 and set a “market outperform” rating for the company in a report on Monday, August 3rd. Leerink Partners dropped their price target on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research report on Friday, June 5th. Royal Bank Of Canada cut their price target on Stryker from $435.00 to $420.00 and set an “outperform” rating for the company in a research note on Friday, July 31st. Wall Street Zen upgraded Stryker from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Finally, Truist Financial lifted their price objective on Stryker from $330.00 to $340.00 and gave the company a “hold” rating in a report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $386.28.

Insider Activity at Stryker

In other news, insider Dylan Bram Crotty sold 441 shares of the company’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $328.61, for a total transaction of $144,917.01. Following the completion of the transaction, the insider directly owned 6,102 shares in the company, valued at approximately $2,005,178.22. This represents a 6.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Debra King sold 826 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the transaction, the insider owned 6,210 shares of the company’s stock, valued at $2,088,423. The trade was a 11.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 351,267 shares of company stock valued at $118,197,701 in the last quarter. Insiders own 4.60% of the company’s stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.